eunethta

EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT

EUnetHTA 21 – Guidance

D5.1 SUBMISSION DOSSIER GUIDANCE

Version 1.0, 16 December 2022

Template version 1.0, 03/03/22022

Document history and contributors

Version	Date	Description
V0.1	**26/04/2022**	First draft
V0.2	**24/05/2022**	Second draft
V0.3	**29/06/2022**	Final for public consultation
V0.4	**02/11/2022**	Endorsed by CEB
V1.0	**16/12/2022**	Date of Publication

Disclaimer

Participants

Hands-on Group	Haute Autorité de Santé [HAS], France Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [IQWiG], Germany
Project Management	Zorginstituut Nederland [ZIN], The Netherlands
CSCQ/CEB	Agencia Española de Medicamentos y Productos Sanitarios [AEMPS], Spain Austrian Institute for Health Technology Assessment [AIHTA], Austria Belgian Health Care Knowledge Centre [KCE], Belgium Gemeinsamer Bundesausschuss [G-BA], Germany Haute Autorité de Santé [HAS], France Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [IGWiG], Germany Italian Medicines Agency [AIFA], Italy National Authority of Medicines and Health Products [INFARMED], Portugal National Centre for Pharmacoeconomics [NCPE], Ireland National Institute of Pharmacy and Nutrition [NIPN], Hungary Norwegian Medicines Agency [NOMA], Norway The Dental and Pharmaceutical Benefits Agency [TLV], Sweden Zorginstituut Nederland [ZIN], The Netherlands

The work in EUnetHTA 21 is a collaborative effort. While the agencies in the Hands-on Group actively wrote the deliverable, the entire EUnetHTA 21 consortium is involved in its production throughout various stages. This means that the Committee for Scientific Consistency and Quality (CSCQ) reviewed and discussed several drafts of the deliverable before validation. The Consortium Executive Board (CEB) then endorsed the final deliverable before publication.

Associated HTAb & Stakeholders participating in public consultation

The draft deliverable was reviewed by associated HTAb and was open for public consultation between 04.07.2022 and 02.08.2022.

Associated HTA bodies who reviewed	Dachverband der Österreichischen Sozialversicherung, [DVSV], Austria Norwegian Institute of Public Health, [NIPH], Norway Evaluation and Planning Unit – Directorate of the Canary Islands Health Service, [SESCS], Spain Regione Emilia-Romagna, [RER], Italy Health Information and Quality Authority [HIQA], Ireland
Stakeholders who reviewed during public consultation	Advanced Medical Services GmbH (AMS), Germany AstraZeneca (AZ), Global (UK based) DVSV, Austria Ecker + Ecker GmbH (E+E), Germany Edwards Lifesciences, Europe European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium European Union of General Practitioners/Family Physicians (UEMO), Belgium EURORDIS. France F. Hoffmann-La Roche Ltd (Roche), Switzerland GKV-Spitzenverband (GKV-SV), Germany GSK, UK IGES Institut GmbH and HealthEcon AG, Germany International Association of Mutual Benefit Societies (AIM), Belgium Lumanity, *a global company with several European entities, including in Ireland and the Netherlands.* Lymphoma Coalition - Lymphoma Coalition Europe (LCE), France MedTech Europe (MTE) Europe , Belgium Medtronic, Switzerland Microvention Europe (MVE), France SKC Beratungsgesellschaft mbH (SKC), Germany Takeda Pharmaceuticals International AG, Brussels, Switzerland, local operating companies across the European Union The European Socienty for Paediartic Oncology (SIOPE), Belgium Verband Forschender Arzneimittelhersteller (vfa) e.V, Germany PHMR, UK Institut national d'excellence en santé et en services sociaux (INESSS), Canada INTUITIVE, US based (California)

Table of contents

List of abbreviations

Abbreviation	Meaning
AIMD	Active implantable medical device
ATC	Anatomical Therapeutic Chemical (code)
ATMP	Advanced therapy medicinal product
CE	Conformité Européenne
CEB	Consortium Executive Board
CHMP	Committee for Medicinal Products for Human Use
CSR	Clinical study report
CTD	Common technical document
DSM	Diagnostic and Statistical Manual of Mental Disorders
EEA	European Economic Area
EMA	European Medicines Agency
EU	European Union
HTA	Health technology assessment
HTAR	Health technology assessment regulation (Regulation (EU) 2021/2282)
HTD	Health technology developer
ICD	International Statistical Classification of Diseases and Related Health Problems
IVD	In vitro diagnostic medical device
IVDR	In vitro diagnostic medical device regulation (Regulation (EU) 2017/746)
MD	Medical device
MDR	Medical device regulation (Regulation (EU) 2017/745)
MRI	Magnetic resonance imaging
PICO	Population, intervention, comparator, outcome
PIP	paediatric investigation plan
PRIME	Priority medicine scheme of the European Medicines Agency
SmPC	Summary of product characteristics
SSCP	Summary of safety and clinical performance
SSP	Summary of safety and performance
UDI-DI	Unique device identification-device identifier (according to Regulation (EU) 2017/745)

I Introduction

According to Regulation (EU) 2021/2282 on health technology assessment (HTAR), a dossier including the information required for health technology assessment (HTA) of a medicinal product or medical device (MD) shall be submitted by the health technology developer (HTD). This dossier forms the basis for the assessment process and the joint clinical assessment report.

The current requirements for the content of a European HTA dossier are set out in Annex I and Annex II to the HTAR (Article 9.4): "The dossier for medicinal products shall include the information set out in Annex I. The dossier for medical devices and in vitro diagnostics medical devices shall include the information set out in Annex II".

This guidance indicates an appropriate format for the information and data that are required for submission in accordance with the HTAR. HTDs shall not modify the overall organisation of the dossier as outlined in this guidance. The guidance only includes a high-level structure. Within this structure, the presentation of information and data can be developed to provide the best possible presentation of the information to facilitate understanding and assessment of the data.

This guidance is a first component of the overall framework of submission guidance. It describes the overall structure and the general requirements for the submission. In addition to the requirements laid down in this guidance, further guidance adopted by the Consortium Executive Board (CEB) has to be taken into consideration when preparing a dossier for a joint clinical assessment. This will comprise a template for the submission dossier and a set of table and figure templates further specifying technical requirements and methodological guidance.

II General requirements for the dossier

According to Regulation (EU) 2021/2282 (Article 9.3) the dossier shall meet the following requirements:

- The evidence submitted is complete with regard to the available studies and data that could inform the assessment.
- The data have been analysed using appropriate methods to answer all the research questions for the assessment.
- The presentation of the data is well structured and transparent, thereby allowing for appropriate assessment within the limited timeframes available.
- The dossier includes the underlying documentation with respect to the information submitted, thereby allowing the assessor and co-assessor to verify the accuracy of that information.

III Overview of the dossier structure

The dossier shall inform the joint clinical assessment of the health technology in question. Thus, it shall provide information for the clinical domains for HTA: the health problem addressed by the technology under assessment and the current use of other health technologies addressing the health problem, a description and technical characterisation of the health technology, and the relative clinical effectiveness and relative safety of the health technology.

The presentation of information in the dossier is organised into six sections as depicted in Figure 1.



Figure 1. High-level structure of the dossier.

IV Structure and content of the dossier

1 Overview

1.1 Administrative information

This section of the dossier shall include information on the HTD responsible for submission of the technology under assessment for regulatory approval as well as on the HTD responsible for the submission dossier.

If the technology under assessment has already been assessed under the HTAR, this shall be described.

1.2 Executive summary

This section shall include an executive summary of the content of the dossier focusing on the assessment scope, the available evidence to answer the PICO question(s) of the assessment scope and the results on relative effectiveness and relative safety.

2 Background

2.1 Characterisation of the health condition to be treated or diagnosed

2.1.1 Overview of the health condition to be treated

In order to provide an overview of the health condition, this section of the dossier shall:

- Describe the disease or health condition in the scope of this joint clinical assessment, including criteria for diagnosis, if available, using a standardised code such as the International Statistical Classification of Diseases and Related Health Problems (ICD) code or Diagnostic and Statistical Manual of Mental Disorders (DSM) code (and the version of the code).
- If relevant, describe the main subtypes and/or stages of the disease or health condition.
- Include any prognostic factors that may affect the course of the disease or health condition and the prognosis of the health condition without the new treatment.
- Present an estimate of the most recent prevalence and/or incidence for the health condition in Europe (countries in which the HTAR is in effect) and, if applicable, describe any profound differences between European countries.
- Describe the symptoms and burden of the health condition for patients (including aspects such as pain, disability, psychosocial issues, and other determinants of morbidity and quality of life from a patient perspective).
- Where relevant briefly describe the organisational and societal impact of the health condition and its treatment, giving some context for interpretation of outcomes; this description is specifically relevant for health conditions that result in disability and/or a need for a family caregiver, and for treatments that result in major organisational changes

to the health care system, e.g. due to manufacturing constraints (e.g. CAR-T cells) or major associated procedures (e.g. organ transplant).

References for the statements shall be provided.

2.1.2 Characterisation of the target population

The target population(s) is (are) defined in the assessment scope. The default target population in the joint clinical assessment will be the claimed indication submitted by the HTD to the regulatory body or the indication wording from the Committee for Medicinal Products for Human Use (CHMP) positive opinion or summary of product characteristics (SmPC) for medicinal products, the Conformité Européenne (CE) marking, or the summary of safety and clinical performance (SSCP) for an MD or the summary of safety and performance (SSP) for an in vitro diagnostic medical device (IVD). Based on the assessment scope, subpopulations of the population according to the indication wording may be relevant.

In order to characterise the target population(s) this section of the dossier shall:

- Describe and justify the proposed position of the target population(s) in the patient pathway of care.
- If relevant, take into account gender- and age-specific characteristics.
- Describe any subpopulations (including the criteria for identifying them) if specifically defined in the assessment scope.
- Describe the natural progression of the disease (by subpopulation, if appropriate).

References for the statements shall be provided.

2.1.3 Clinical management of the health condition

In order to characterise the clinical management of the health condition, this section of the dossier shall:

- Describe the clinical pathway of care for the health condition being considered in the joint clinical assessment, as well as, if relevant, for different stages and/or subtypes or subpopulations of the health condition, with diagrams of the care pathway(s) that include alternative interventions.
- If clinical pathways vary substantially between European countries (countries in which the HTAR is in effect), describe these variations in care.
- Include a list of relevant clinical guidelines (at the European level).

References for the statements shall be provided.

2.2 Characterisation of the medicinal product/medical device under assessment

2.2.1 Characteristics of the health technology

For medicinal products, the characteristics of the technology shall include:

- The nonproprietary name;
- The proprietary name;
- The HTD submitting an application to the European Medicines Agency (EMA);
- The drug class;
- The active substance(s);
- A characterisation of the mechanism of action;
- Drug interactions;
- The pharmaceutical formulation(s); and
- The Anatomical Therapeutic Chemical (ATC) code.

For medicinal products, the characterisation of administration and dosing (by (sub)population or patient group, if appropriate) shall include, as appropriate:

- The method of administration;
- The doses and dosing frequency;
- The average length of a course of treatment;
- The anticipated average interval between courses of treatment;
- The anticipated number of repeat courses of treatment;
- Information on dose adjustments;
- Criteria for the ending of treatment;
- Combination with other interventions;
- The monitoring required during administration or during the treatment period; and
- Concomitant treatments required or recommended, such as fluid support, antiemetic agents, antiviral agents or venous thromboembolism prophylaxis.

For MDs (including IVDs), the characteristics of the technology shall include:

- The trade name of the MD;
- The product type according to the MD regulation (MDR; Regulation (EU) 2017/745) code for MDs or the IVD regulation (IVDR; Regulation (EU) 2017/746) code for IVDs;

- The specific medical purpose(s) of the device according to Article 2(1) MDR;
- Models, references, or software version;
- The basic unique device identification-device identifier (UDI-DI; according to Regulation (EU) 2017/745).
- The MD risk class according to the MDR or IVDR;
- The HTD submitting the dossier (specify whether it is the MD manufacturer or an authorised representative);
- The date on which the MD was first placed on the EU market in the course of commercial activity (excluding investigational device use);
- A product description: composition, technologies involved and technical characteristics ;
- A description of the main stages of the development of the technology, when relevant (e.g. when previous versions of the technology are available, the main changes made to these different versions shall be described);
- If the MD includes connected technology because some or all of the device is software, a specific description is required;
- For medical devices with an embedded decision-making system based on machine learning processes (technologies falling within the scope of artificial intelligence): provide a description of the functions built or evolving using these technologies;
- Magnetic resonance imaging (MRI) compatibility: For implantable MDs liable to give rise to artefacts, the potential impact of these artefacts on MRI interpretation and the associated recommendations for use shall be documented. For active implantable medical devices (AIMDs), specify the limits of compatibility with MRI procedures and the main precautions to be taken. Where applicable, the AIMD deactivation measures required to conduct the test shall be specified.

For MDs (including IVDs), the characteristics of use (by (sub)population or patient group, if appropriate), shall include, as appropriate:

- A description of the mode of action on the pathology or disability.
- The intended purpose and the labelling of the MD.
- The manufacturer’s instructions for use.
- Information on whether the MD device is intended
    - To administer and/or remove a medicinal product,
    - To act as a companion diagnostic
    - To emit hazardous, or potentially hazardous, levels of ionising and/or nonionising radiation, or

- To be operated together with other devices or products.

- A description of (surgical) procedures, services and organisational aspects (including specific technical facilities at hospital) associated with use of the MD shall be provided; the suggested profile and training for users as outlined in the SSCP shall be provided.

References for the statements shall be provided.

2.2.2 Requirements/instructions for use

If applicable, the equipment required to use the technology shall be described, including any specific tests or investigations required (e.g., biomarker testing, companion diagnostics, amount and type of biological material needed for IVD). If all such equipment is described in the section above, state here that there are no additional requirements.

If applicable, any supplies (except for generic supplies) required to use the technology shall be described .

References for the statements shall be provided.

2.2.3 Regulatory status of the technology

For medicinal products, the regulatory status of the technology shall be clarified in a tabular description of the marketing authorisation status applied for at the EMA, including any specific regulatory designations or approval schemes at the European level, such as orphan status, advanced therapy medicinal product (ATMP), conditional marketing authorisation, the EMA priority medicine scheme (PRIME) or paediatric investigation plan (PIP). Information on the regulatory status at the national level, such as compassionate use or early access programmes shall also be provided for EEA countries. Any marketing authorisations in Europe for other indications that are not included in the joint clinical assessment shall also be described (including the organisation issuing approval, the verbatim wording of the indication and the date of approval). Additional indications already submitted to EMA shall be listed. An overview of the regulatory status in Australia, Canada, China, Japan, the United Kingdom and the United States of America shall be provided. Any contraindications or groups for whom the technology is not recommended shall be listed.

For MDs (including IVDs), the regulatory status of the technology shall be clarified in a tabular description, including: the MD risk class according to the MDR; name, identification number and country of the notified body that issued the CE marking; date of the initial CE marking and the expiry date of the current certificate; the verbatim wording of the CE marking indication (i.e., the intended use according to the conformity assessment, including indications and contraindications; and the date of the expert panel opinion.

References for the statements shall be provided.

2.3 Joint scientific consultation related to the joint clinical assessment

Any joint scientific consultations for the health technology under assessment at the European level shall be listed. If a health technology has been the subject of a joint scientific consultation, any deviation from the recommended evidence shall be explained.

3 Research question and assessment scope

In the context of European HTA, the assessment scope reflects policy questions from the different health care systems in which the HTA shall be used. It translates the policy question(s) into research question(s) with a standard format, called PICO question(s). The assessment scope means the set of parameters for joint clinical assessment in terms of:

- The patient population or populations (P),
- The intervention or interventions (I),
- The comparator or comparators (C) and
- The health outcomes (O)

requested jointly by member states. This scope is identified in a scoping process initiated by the designated subgroup for a given joint clinical assessment.

The assessment scope shall be inclusive and reflect the needs of member states in terms of parameters and the information, data, analysis and other evidence to be submitted by the HTD.

The HTD is informed about the assessment scope with a request for submission of the dossier on which the joint clinical assessment will be based. The assessment scope as requested specifies the research question elaborated in the submission dossier, that is, it forms the basis for the content of the submission dossier and shall be provided in the corresponding section of the dossier (Research question and assessment scope). The dossier submitted by the HTD shall address all the PICO questions included in the assessment scope and provide the evidence available to appropriately answer all the PICO questions. Whenever a PICO question cannot be addressed due to lack of data (e.g. no evidence from direct comparison and unfeasible indirect comparison), a justification shall be provided by the HTD.

For cases in which the scoping process identified more than one PICO question, these shall be presented separately and transparently.

4 Methods used in the development of the dossier content

A description of methods used in the development of the dossier content is required to allow assessment of the appropriateness of the methods and of the validity and certainty of the results presented in the dossier.

The methods used in the development of the dossier content shall be based on the international standards of evidence-based medicine. The methods shall also follow methodological guidance adopted by the CEB. Any deviations from this guidance shall be described and justified.

The data presented in the dossier shall have been analysed using appropriate methods to answer all research questions of the joint clinical assessment.

4.1 Criteria for selecting studies for joint clinical assessment

Based on the assessment scope and the methodological guidance applicable, inclusion and exclusion criteria for studies to be considered in the joint clinical assessment shall be specified. This specification has to be provided for each PICO question, as appropriate. These criteria shall be used to select the studies from the results of the systematic information retrieval process for the joint clinical assessment.

4.2 Information retrieval and selection of relevant studies

The joint clinical assessment shall be based on the complete evidence available. Specifically, the submission dossier that forms the basis of the joint clinical assessment shall be complete with regard to the studies and data available that could inform the assessment. This completeness can only be achieved via systematic information retrieval.

Systematic information retrieval

The HTD shall conduct a systematic information retrieval process to identify the evidence to be used for preparation of the dossier. This information retrieval shall include the following sources:

- Studies performed or sponsored by the HTD

  To meet the requirements of the HTAR, the HTD shall provide with the dossier all up-to-date published and unpublished information, data, analyses and other evidence from studies on the health technology for which the HTD was a sponsor. Furthermore, all information available on ongoing or discontinued studies with the health technology for which the HTD is a sponsor or otherwise financially involved has to be made available.
- Corresponding information on studies by third parties, if available, shall also be provided.
- Bibliographic databases
- Study registries and study results registries (clinical trial databases)
- For medicinal products, the clinical safety and efficacy data included in the submission file to the EMA
- For MDs, the clinical evaluation assessment report and the manufacturer’s clinical evaluation documentation submitted to the notified body

These sources shall be systematically searched for studies and analyses that are relevant for the joint clinical assessment according to the assessment scope. Full documentation for the searches shall be included in the dossier.

In addition, the HTD shall include information on HTA reports available on the health technology subject to the joint clinical assessment from EEA countries and from Australia, Canada, the United Kingdom and the United States of America. Furthermore, information on studies based on (patient) registries shall be provided in the dossier. This information shall also be provided based on systematic searches in appropriate sources.

Acceptable search dates (latest date for a search for a given joint clinical assessment) are defined in the applicable guidance adopted by the CEB.

Selection of relevant studies

Relevant studies to be included in the dossier, specifically for description of the relative effectiveness and relative safety, shall be selected according to inclusion and exclusion criteria defined for the joint clinical assessment of the health technology. The selection process shall be performed according to methodological guidance adopted by the CEB and shall be documented in the dossier.

4.3 Data analysis and synthesis

The data presented in the dossier shall have been analysed using appropriate methods. Evaluation of the methods applied by the HTD is part of the joint clinical assessment process. This evaluation addresses the appropriateness of the methods and the validity and certainty of the results on relative effectiveness and relative safety generated using these methods. To allow this assessment, the dossier shall include a transparent description of the methods used. Therefore, the section on data analysis and synthesis shall, among others, cover the following topics:

- A description of the design and methodology of the studies included

  The description of the design and methodology of the included studies shall follow the standards of evidence-based medicine and the guidance adopted by the CEB. This section shall specify the items used to describe the design and methodology of the studies.

- A description of the results from the individual studies

  First, the results from individual studies shall be presented separately in the dossier, irrespective of any potential synthesis of these results (e.g., in meta-analyses). This section shall describe the items to be presented for the patient characteristics and endpoints.

- Meta-analyses

If appropriate, the studies available shall be synthesised quantitatively via meta-analyses. The methods applied shall be described in this section. The methods used for meta-analyses shall follow the guidance adopted by the CEB.

- Indirect comparisons

  If indirect comparisons are considered, these shall be conducted using appropriate methods. Any assumptions underlying the analyses shall be specified and the degree to which these assumptions are met shall be described. The methods used for indirect comparisons shall follow the guidance adopted by the CEB.

- Sensitivity analyses

  Sensitivity analyses shall be performed, if required, to investigate the impact of methodological factors on the robustness of the results. The methods used for sensitivity analyses shall follow the guidance adopted by the CEB.

- Subgroup analyses and other effect modifiers

  Effect modification shall be investigated via subgroup analyses. The methods used for subgroup analyses shall follow the guidance adopted by the CEB.

- Specification of further methods as required

  Any methods used in deriving results in the dossier shall follow the guidance adopted by the CEB, if available.

5 Results

The presentation of results shall use text, figures and tables as appropriate. The results presentation shall consider guidance adopted by the CEB.

5.1 Results from the information retrieval process

Results from the different steps of the information retrieval process shall be presented transparently in the submission dossier. This presentation shall include:

- A list of studies conducted by the HTD

  The list of studies conducted by the HTD shall include all studies submitted to the regulatory body for medicinal products (marketing authorisation studies from the clinical safety and efficacy data included in the submission file to the EMA) or submitted to the notified bodies for MDs (studies from the clinical evaluation documentation), as well as all studies sponsored by the HTD or in which the HTD was or is financially involved. The listing shall be restricted to studies involving patients in the indication (for medicinal products) or intended use (for MDs/IVDs) for which the submission dossier is prepared.

- Corresponding information on studies by third parties, if available, shall also be provided.

- Studies identified in searches in bibliographic databases

  The results from searches in bibliographic databases shall be presented according to the methodological standards.

- Studies from searches in study registries/study result registries (clinical trial databases)

  The results from searches in study registries/study results registries shall be presented according to the methodological standards.

  For each of the information retrieval steps, the studies not considered in the joint clinical assessment shall be identified. For each of these studies, the reason for exclusion shall be specified.

List of studies included overall and by PICO question

The study pool resulting from all searches shall be presented transparently. In addition to an overall study pool used in the submission dossier, the study pool(s) used to inform the individual PICO question(s) shall be specified.

5.2 Characteristics of the studies included

An overall description of the study design and the study population shall be provided for all studies included in the description of relative effectiveness and safety in any of the PICO questions according to the requirements laid down in guidance adopted by the CEB.

5.3 Study results on relative effectiveness and relative safety

The HTD shall provide aggregated data (results on relative effectiveness and safety) according to the assessment scope in the submission dossier. The analyses presented in the dossier shall take the guidance adopted by the CEB into consideration.

The assessment scope might include one or more PICO question(s) for which the available evidence has to be provided in the dossier. To achieve a transparent data presentation, the results for effectiveness and safety shall be described by PICO question.

The first defining item of a PICO question is the patient population in which the relative effects of an intervention versus a comparator are investigated. The data presentation shall first be structured by patient population. Within a given population, more than one PICO question(s) might have to be investigated, for example, because of different comparators. These can be sequentially presented within one chapter as depicted in the following structure of sections.

5.3.1 Results for the patient population < to be specified>

For each patient population specified in the PICO question(s) in the assessment scope, a separate section shall be provided. Within this section, the results for all PICO question(s) addressing this patient population shall be presented in subsections.

5.3.1.1 Patient characteristics

The patient characteristics from all studies covering the relevant patient population included in any of the PICO question(s) addressing this population shall be presented. The data presentation shall take guidance adopted by the CEB into consideration.

5.3.1.2 Outcomes for the PICO <to be specified>

For each PICO question addressing the patient population specified in Section 4.3.1, a list of the studies included in the investigation shall be provided. Furthermore, an overview of available outcomes by study shall be presented. The presentation of any outcomes not included in the PICO shall be justified. The data presentation shall include the results from all individual studies as well as any syntheses of results, for example, from meta-analyses. The presentation of information for the individual outcomes shall follow the submission dossier guidance and the submission dossier template.

For any additional PICO question for a given patient population required according to the assessment scope, a new subsection presenting the results for outcomes for this PICO question shall be added.

6 List of references

Appendix A Tabular listing of all studies included in the description of relative effectiveness and safety

Appendix B Underlying documentation for medicinal products

B.1 Full texts of references

Full texts of any references provided in the dossier and listed in the respective reference lists shall be provided. The reference list of the submission dossier shall be provided in a standard format that can be read by literature management programs.

B.2 Documentation of information retrieval

The documentation of information retrieval shall be provided in a standard format that can be read by literature management programs.

B.3 Programming code for programs used for analyses

Program code and relevant output shall be provided if the analyses and corresponding calculations cannot be described by a specific standard method (e.g. Mantel-Haenszel).

B.4 Study reports

The Clinical Study Reports (CSR), including study protocols and statistical analysis plans, required by the Regulation and any guidance adopted by the CEB shall be provided as part of the underlying documentation of the dossier. The technical specifications to be followed for submitting the CSRs will be provided by guidance from the CEB.

B.5 Clinical safety and efficacy data included in the submission file to the European Medicines Agency

Clinical safety and efficacy data included in the submission file to the EMA shall be provided as sections 2.5, 2.7.3 and 2.7.4 from the Common Technical Document (CTD, format of submission to EMA) and as CSRs (see section B.4 Study reports).

B.6 HTA reports of the health technology subject to the joint clinical assessment

If HTA reports from earlier joint clinical assessments or from other jurisdictions are available, these shall be included.

B.7 Information on studies based on registries

If any studies with the health technology under assessment from patient registries are available, these shall be included.

B.8 Information on joint scientific consultations

If a health technology has been subject to a joint scientific consultation, the recommendations shall be provided.

Appendix C Underlying documentation for medical devices

C.1 Full texts of references

Full texts of any references provided in the dossier and listed in the respective reference lists shall be provided. The reference list of the submission dossier shall be provided in a standard format that can be read by literature management programs.

C.2 Documentation of information retrieval

The documentation of information retrieval shall be provided in a standard format that can be read by literature management programs.

C.3 Programming code for programs used for analyses

Program code shall be provided if the analyses and corresponding calculations cannot be described by a specific standard method (e.g. Mantel-Haenszel).

C.4 Study reports

The Clinical Study Reports (CSR), including study protocols and statistical analysis plans, required by the Regulation and any guidance adopted by the CEB shall be provided as part of the underlying documentation of the dossier. The technical specifications to be followed for submitting the CSRs will be provided by guidance from the CEB.

C.5 For medical devices: clinical evaluation documentation

The documentation provided shall include the clinical evaluation assessment report, the manufacturer's clinical evaluation documentation submitted to the notified body pursuant to Section 6.1, points (c) and (d), of Annex II to Regulation (EU) 2017/745 and the scientific opinion provided by the relevant expert panels in the framework of the clinical evaluation consultation procedure. In addition, the EU declaration of conformity of the medical device, the CE marking certificate(s) relating to the medical device, the instructions for use and the validated SSCP (for MD) and SSP (for IVD) shall be provided.

C.6 For in vitro diagnostic medical devices: performance evaluation documentation

The documentation provided shall include the performance evaluation report of the manufacturer, the manufacturer's performance evaluation documentation, referred to in Section 6.2 of Annex II to Regulation (EU) 2017/746, the scientific opinion provided by the relevant expert panels in the framework of the performance evaluation consultation procedure and the report of the Union reference laboratory.

C.7 HTA reports of the health technology subject to the joint clinical assessment

If HTA reports from earlier joint clinical assessments or from other jurisdictions are available, these shall be included.

C.8 Information on studies based on registries

If any studies with the health technology under assessment from patient registries are available, these shall be included.

C.9 Information on joint scientific consultations

If a health technology has been subject to a joint scientific consultation, the recommendations shall be provided.